PoC

Proof of Clinical Evidence
Program Highlights

Become the program exclusively tailored specially for healthcare sysyem.

01

Exclusive Access to Hospital Resources

Create a direct and exclusive access to hospital resources for customized collaboration.

02

Unlock Future Funding Opportunities

Raise the possibility for future funding and obtain the chances of getting the fund from BE Health Ventures.

03

Accelerate Growth and Market Expansion

Help teams achieve specific milestones in order to accelerate growth and expand the market in Asia.

04

1-on-1 Expert Consultation

Get 1-on-1 consults from Healthcare experts to develop a sound business model.

05

Key highlights of the 2026 cohort include:

• More in-depth commercial adoption feasibility assessments report from a hospital-wide operational perspective, along with clinical application use-case discussions
• Hands-on hospital-based demonstrations and physician user experiences, along with corporate visits and real-world product validation opportunities
This enhanced program structure is designed to support startups in transitioning from PoC validation to actual deployment and commercial collaboration.

Hospital Resources

Taipei Medical University

Taiwan’s first international medical university accelerator with a perfect medical market place, clinical advantages, biomedical and artificial intelligence talents, focusing on digital health, artificial intelligence and medical equipment, assisting start-up to raise funds , community and international resource linkage, coaching  and reducing development risks, clinical trial planning, establishing medical pathways. Assist the startup teams to make good use of Taipei medical University clinical field and dedicated team of professional physicians, counsel the startup team’s product clinical verification strategy, enable the startup team to accelerate the products into the clinical field, provide entrepreneurial funds and assist in raising funds, Establish engagement with international accelerator and entrepreneurial ecosystem.

Show Chwan Health Care System

Show Chwan health care system is the largest privately-owned hospital group in Taiwan, with 10 hospitals, over 3,700 beds, and 6,000 employees.  Innovation and patient-oriented service have always been its core values since being founded in 1973 by Dr Min-ho Huang.  The mission is to offer leading-edge technology and services to under-served areas.  In addition to tertiary medical services, it also has facilities catering to elderly, maternal health, and comprehensive cancer care. Originated from Ircad located in Strasbourg, France, it is the largest and most advanced minimally invasive training center in Asia.  Established 2008,  it has trained over 12,000 physicians from over 80 countries, running close to 100 workshops annually.  In addition to surgical training, it also boasts an advanced research center as well as an incubation center for medical start-ups.  It is the perfect hub for innovations.  Located in Lugang Industrial Park, in the center of Taiwan, it is an ideal center with many resources necessary for the success of med-tech start-ups.

Program

Workshops

Courses

Coach

Demo Day

Corporates collaboration

Timeline

2025 Dec.-Jan.
Recruiting

2026 Mar.
Kick-off

2026 Late Jul.
Demo Day

2026 Feb.
Selection

2026 Mar.-Aug.
Mentorship

FAQ

✦ Why is Taiwan a good ecosystem for you to come and validate your solution for the Asia market?

– Location: Average of 2h55m flight to six major cities in western Pacific.
– Medical Resources: Collected over 20 years of digitized, single- payer medical data from NHI.
– Technology: Strength in creating proprietary technology, R&D and manufacturing.
– Innovation: Taiwan is focused on having an innovation-driven economy.

The BE PoC Accelerator Program provides the ideal opportunity for international startups to explore business opportunities in Asia. With our network of hospitals, startups can explore unmet clinical needs through needs validation, establishing a hospital pilot site, and access to medical resources. Startups interested in clinical trial, manufacturing, data access and fundraising resources will also benefit from our network across Taiwan and Asia.

The program runs for a 20-24 week period, but a full-time commitment is not required. The main reason for the length of the program is to facilitate the proper engagement with our hospital partners and the relevant clinicians. This is something that usually takes time and requires multiple engagements. Weekly, the time allocation for the program will roughly be about 3-5 hours depending on the course material for the week and the number of hospital engagements.
Startups that apply to our program are allocated to one of our hospital partners depending on their area of focus. This is as each hospital has different areas of interest and resources to help startups. Taipei Medical University is focused on working with startups in the areas of digital health, artificial intelligence, and medical devices. Show Chwan Healthcare System is dedicated to working with startups that focus on minimally invasive surgery, robotic surgery, and smart surgical room solutions. If you are uncertain which hospital to apply for, please reach out directly to the BE team or apply to the program that you believe is most suitable and we will make any changes during the selection period.

According to the experience from previous batches, the chances for the accelerated companies to be invested are 10%. The primary concern of the investment evaluation is whether the company can provide relevant information for us to conduct a certain degree of due diligence, while the other key aspect is the strategic synergy between BE and the company.

We conduct due diligence based on the stage of the company, and the main categories include Business, Technology, Finance, Regulation, and Legal and Related Matters. In general, it will take about three months from the first meeting to the final decision of the Investment Committee.

Since the strategic synergy between BE and the company is a key aspect of our investment evaluation, as a hospital VC, the progress of the collaboration between the companies and our two partner hospitals will play a critical role in due diligence.

Yes. The PoC Program is a fee-based program.
 
‣Application & evaluation stage: Free of charge
(No fees are required when submitting an application. All applicants will undergo a joint evaluation by BE Health and hospital partners.)
‣Upon final selection and entry into the PoC kickoff phase: USD 6,500
 
The Program Service Fee is required only after a startup is officially selected and proceeds to the PoC execution stage.
👉 This fee represents a cost-sharing contribution for clinical adoption and PoC execution, rather than a tuition or participation fee.
Unlike previous cohorts that primarily focused on acceleration and early-stage validation, the 2026 PoC Program introduces an enhanced model in close collaboration with hospital partners, with a stronger emphasis on hospital adoption and real-world implementation.
 
Key highlights of the 2026 cohort include:
• More in-depth commercial adoption feasibility assessments report from a hospital-wide operational perspective, along with clinical application use-case discussions
• Hands-on hospital-based demonstrations and physician user experiences, along with corporate visits and real-world product validation opportunities
 
This enhanced program structure is designed to support startups in transitioning from PoC validation to actual deployment and commercial collaboration.
The total value of the PoC Program is estimated at USD 35,000.
Starting from the batch in 2026, selected startups are required to pay only a USD 6,500 Program Service Fee, while the remaining USD 28,500 in value is provided through sponsored resources and direct contributions from BE Health, hospital partners, corporate partners, and its ecosystem partners.
This fee is not a “guaranteed adoption fee.”
It is used to support the actual resources invested by hospitals and corporate partners in adoption assessment and execution.
Even if formal adoption does not take place in the end, startups will still complete the full clinical and commercial / fundraising process, and the outcomes of this process remain valuable, reusable assets that can be leveraged for future opportunities.